Pharmos
Corporation to Present at the Rodman & Renshaw
Techvest Healthcare Conference
Iselin NJ, October
15, 2003 – Pharmos Corporation (Nasdaq:
PARS and Nasdaq Europe: PHRM) announced today Dr. Haim
Aviv, Chairman & CEO, will present to institutional
investors and analysts attending the Rodman & Renshaw
Techvest Healthcare conference in Boston on Tuesday, October
21, at 3:00 p.m. Eastern Time. Pharmos’ presentation
will concentrate on dexanabinol, the Company’s lead
compound under development, currently being tested clinically
for traumatic brain injury (Phase III trial) and mild
cognitive impairment in cardiac surgery patients (Phase
IIa). The presentation will also outline other areas of
therapeutic potential held within the Company’s
rich neurological pipeline.
A simultaneous audio-only webcast of Pharmos’
presentation will be available at http://www.wallstreetwebcasting.com/webcast/rrshq/pars/,
and will be archived for a limited time after the conference.
The slides to the presentation will be available on Pharmos’
website at http://www.pharmoscorp.com/ .
Pharmos discovers, develops, and commercializes
novel therapeutics to treat a range of indications, in
particular neurological and inflammation-based disorders.
The Company's first neuroprotective product is dexanabinol,
a tricyclic dextrocannabinoid, currently undergoing clinical
testing as a treatment for TBI and as a preventive agent
against post-surgical cognitive impairment. Other dextrocannabinoid
compounds and selective CB2 receptor agonist compounds
from Pharmos' proprietary synthetic cannabinoid library
are being studied in pre-clinical programs targeting a
variety of other disorders.
Statements made in this press release related
to the business outlook and future financial performance
of the Company, to the prospective market penetration
of its drug products, to the development and commercialization
of the Company’s pipeline products and to the Company’s
expectations in connection with any future event, condition,
performance or other matter, are forward-looking and are
made pursuant to the safe harbor provisions of the Securities
Litigation Reform Act of 1995. Such statements involve
risks and uncertainties which may cause results to differ
materially from those set forth in these statements. Additional
economic, competitive, governmental, technological, marketing
and other factors identified in Pharmos’ filings
with the Securities and Exchange Commission could affect
such results.
Statements made in this press release
related to the business outlook and future financial performance
of the Company, to the prospective market penetration
of its drug products, to the development and commercialization
of the Company's pipeline products and to the Company's
expectations in connection with any future event, condition,
performance or other matter, are forward-looking and are
made pursuant to the safe harbor provisions of the Securities
Litigation Reform Act of 1995. Such statements involve
risks and uncertainties which may cause results to differ
materially from those set forth in these statements. Additional
economic, competitive, governmental, technological, marketing
and other factors identified in Pharmos' filings with
the Securities and Exchange Commission could affect such
results.
back
to News Room
